Skip to main content

Gilead Shifting Patients To Newly Approved Drug Descovy

Gilead Shifting Patients To Newly Approved Drug Descovy

Gilead Shifting Patients To Newly Approved Drug Descovy

Introduction

Gilead is working to shift its Truvada pre-exposure prophylaxis (PrEP) users to Descovy, the newer HIV drug approved by the FDA for PReP treatment.

Descovy, known as tenofovir alafenamide (TAF), is a newer generation of HIV drugs that can be taken in lower doses and still be effective. The users can avoid the risk of serious kidney problems and fractures,  which are otherwise caused while taking Truvada and other TDF-based drugs.

Truvada, which contains antiretroviral tenofovir disoproxil fumarate (TDF), was approved in 2004 for the treatment of HIV. Several lawsuits were filed against Gilead, alleging that the manufacturer failed to warn about their tenofovir disoproxil fumarate HIV medications that led to kidney problems and bone loss. The lawsuit also alleges that the manufacturer slowed the development of TAF-based drugs and waited to expire the patent protection. Gilead now has patent protection for brand-name HIV treatments until at least 2032.

According to an analysis by Jefferies & Company analyst Michael Yee, around 10% of users are already converted to use the newer drug, and the manufacturer is on track to convert about 50% to 60% of all users.

TDF lawsuits are consolidated under MDL-2881, IN RE: Tenofovir Disoproxil Fumarate Products Liability Litigation, filed on December 19, 2018, in the Judicial Panel on Multidistrict Litigation.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

Purdue, Sacklers Agree to $7.4B Opioid Settlement

Categories: Opioids

Purdue Pharma and its owners, the Sackler family, have agreed to a $7.4 billion settlement to resolve thousands of lawsuits accusing the…

Paraquat Trials Scheduled for October 2025 & April 2026

Categories: Paraquat

A U.S. District Judge overseeing thousands of federal

UGA College of Pharmacy Gets $1M+ to Fight Opioid Crisis

Categories: Opioids

Faculty from the University of Georgia’s College of Pharmacy have been awarded a nearly $1.2 million grant from the Georgia Opioid Crisis…

Get 5 Free Medical Record Reviews – No Risk, No Contracts!      
Only 10 firms will be accepted!

Valid until February 28, 2025.